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present in 2/6 FLU/BU and 4/9 FLU/MEL evaluable patients. Six
of 12 patients in the FLU/BU died of relapse (n4) and/or infec-
tion (n2, 1 within d100 ) and 3 of 10 patients in the FLU/MEL
died of relapse. In conclusion, since in allogeneic PBSC transplan-
tation the FLU/BU regimen seems to have a myelotoxicity com-
parable to FLU/MEL, it could be used in allotransplant for elderly
patients and may represent a platform for donor lymphocyte infu-
sions in high risk patients.
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ALEMTUZUMAB IMMUNOTHERAPY PROVIDES EFFECTIVE CYTORE-
DUCTION PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION FOR
REFRACTORY LYMPHOPROLIFERATIVE DISORDERS
Voralia, M.1,2; Hasegawa, W.1,2; McAllister, R.2; Evjen, A.2; Briggs,
S.2; Doell, H.2; Danyluk, P.2 1. University of Saskatchewan, Saskatoon,
SK, Canada; 2. Saskatchewan Cancer Agency, Saskatoon, SK, Canada.
Introduction: The optimal cytoreductive therapy for refractory
chronic lymphoproliferative disorders prior to allogeneic stem cell
transplantation is not well deﬁned. Immunotherapy may represent
an alternative cytoreductive strategy in chemotherapy refractory
disease. We assessed the role of alemtuzumab (anti-CD52, CAM-
PATH) immunotherapy in reducing disease bulk pretransplant in
a pilot single center clinical protocol. Patients and Methods:
Patients with CLL and lymphoplasmacytic lymphoma (LPL) re-
fractory to at least two prior lines of chemotherapy, age less than 65
years, and adequate organ function received alemtuzumab mono-
therapy 30 mg. intravenously thrice weekly for 8–12 weeks. Mo-
lecular, hematologic, and radiological responses were measured.
Transplantation conditioning consisted of Fludarabine/Melphalan
or BEAM. Results: Between 10/2002 and 10/2004, 7 patients (6
refractory CLL, 1 refractory LPL) received alemtuzumab cytore-
duction and allogeneic stem cell transplantation. All patients had
received prior ﬂudarabine or alkylator therapy; 1 had received
rituximab. High-risk cytogenetic markers (p53 or Rb1 deletions)
were present in 4 of 6 CLL patients, as assessed by FISH. Marrow
involvement decreased from a mean of 80% pre-alemtuzumab to
15% post; 3 patients attained complete marrow clearance. Hema-
tologic remission following alemtuzumab was achieved in 4 of 6
CLL patients. Partial (3/7) or complete (4/7) molecular remission
was achieved in all patients after immunotherapy. Four patients
exhibited partial radiologic responses; 3 were unchanged. Adverse
effects were rare (CMV viremia in 2 patients; moderate cytopenias
requiring brief therapy interruption in 4). All 7 patients proceeded
to allogeneic stem cell transplantation (4 MRD, 3 MUD), one in
clinical relapse. Neutrophil engraftment was rapid (less than 20
days); one patient had delayed platelet engraftment. Although early
to assess long-term disease response, 4/4 evaluable patients have
achieved a complete molecular, hematologic, and radiologic re-
sponse at 6 months post-transplant; one patient remains in com-
plete remission at 2 years. One patient died of sepsis at 3 months.
Conclusion: Alemtuzumab immunotherapy is an effective cytore-
ductive regimen for chemotherapy-refractory lymphoproliferative
disorders prior to allogeneic stem cell transplantation, and bears
testing in a larger multi-centre Phase II/III protocol.
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THE FREQUENCY OF EARLY COMPLICATIONS AFTER ALLOGENEIC HE-
MATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) WITH MYELOA-
BLATIVE (MA) AND NON-MYELOABLATIVE (NMA) CONDITIONING
REGIMEN
Golovchenko, R.A.; Moiseev, S.I. The Russian Institute of Hematology
and Transfusiology, St-Petersburg, Russian Federation.
The frequency of early complications (before 100 days) of HSCT
was measured on 38 patients (pts) with hemoblastosis, underwent
allogeneic HSCT (allo HSCT) from HLA-matched related donors
(median age 24.4 	 1.8). Conditioning regimens were myeloabla-
tive in 28 patients (73.7%, median age 21 	 2.0) and consist
BuCy, and NMA in 10 patients (26.3%, median age 29.9 	 3.6),
consist of FluBuALG or FluBuAlkeran. In group of MA
HSCT 13 patients had CML, 9 - ALL, 5 - AML and 1 - MDS. In
group of NMA HSCT 6 patients had CML, 2 - ALL, 1 - AML, 1
- MDS. The frequency of bacterial infectious complications in
NMA HSCT group was 21.4% and in MA HSCT group 20%
(p0.05). The frequency of febrile neutropenia was signiﬁcantly
lower in NMA HSCT group: 30% and 67,8% respectively
(p
0.05). Viral complications was observed in 14 (50%) patients in
group of MA HSCT and in 5 patients (50%) in NMA group. 8 pts
(28.6%) in MA group developed CMV viremia and 4 pts (40%) in
NMA group (p0.05). Herpes simplex infection was diagnosed in
6 pts (21.4%) in group of MA HSCT and in 1 pt (10%) in NMA
HSCT group (p0.05). Hemorrhagic complications were ob-
served in 14 patients with MA HSCT (50%) and in 4 (40%) with
NMA HSCT (p0.05). Acute graft versus host disease (GVHD)
grade 2–4 was observed in 5 patients with MA HSCT (17.8%) and
in 1 pt (10%) in group of NMA HSCT (p0.05) and chronic
GVHD was developed in 9 pts in MA HSCT group and in 1 pt in
NMA HSCT group (p0.05). The toxicity of conditioning regi-
mens (only grade 3–4 were considered) for cardiovascular system
was signiﬁcant lower for NMA HSCT group: 1 pt (10%) and 11
pts (39.2%), (p
0.05). The toxicity for digestive system was lower
in NMA HSCT group too: 5 pts (50%) and 28 (100%) respectively
(p
0.05). The for respiratory system (7.1% and 0% respectively,
p0.05), urogenital system (25% and 20% respectively, p0.05),
and hepar (46.3% and 40% respectively, p0.05) had no signiﬁ-
cant differences between two groups. 1 pt in group NMA HSCT
had veno-occlusive disease (10%) and no cases in group MA
HSCT (p0.05). The engraftment of stem cells was achieved in
100% cases as in MA as NMA HSCT groups (25.5 	 4.5 and
20.5 	 1.2 days respectively, p0.05). We conclude, that there are
no differences between patients groups with MA and NMA HSCT
in spite of engraftment kinetics, the frequency of infectious com-
plications, the frequency of acute and chronic GVHD. But the use
of NMA HSCT accompany note lower toxicity on cardiovascular
and digestive systems.
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UNRELATED CORD BLOOD TRANSPLANTATION WITH MYELOABLATIVE
CONDITIONING FOR ADULT PATIENTS WITH HEMATOLOGICAL MALIG-
NANCIES
Yamane, A.; Mori, T.; Aisa, Y.; Nakazato, T.; Yamazaki, R.; Ikeda, Y.;
Okamoto, S. Division of Hematology, Keio University School of Medi-
cine, Tokyo, Japan.
Background: Umbilical cord blood (CB) has been rapidly estab-
lished as an alternative source of stem cells to bone marrow or
peripheral blood for unrelated allogeneic hematopoietic stem cell
transplantation. However, concern about the engraftment failure
probably due to low number of stem cells has limited its use
particularly for adult patients. We report the results of unrelated
cord blood transplantation (CBT) for 8 adult patients with hema-
tological malignancies. Patients and Methods: Patients with he-
matological malignancies without a suitable related donor were
eligible. Conditioning consisted of total body irradiation (TBI; 120
cGy) followed by high-dose cytarabine (3 g/m2  8) for myeloid
malignancies, and TBI (120 cGy) followed by high-dose cytarabine
(2 g/m2  4) and cyclophosphamide (60 mg/kg  2) for lymphoid
malignancies. For acute graft-versus-host disease prophylaxis, ta-
crolimus (0.03 mg/kg) and short-term methotrexate (15 mg/m2on
day 1, 10 mg/m2on days 3, 6) were given. All patients received
G-CSF infusion starting on day 1 until neutrophil recovery was
obtained. Cord blood unit was selected according to the nucleated
cell number (more than 2.0  107/kg) and HLA compatibility (less
than serological 2-loci mismatches). Results: Eight patients were
enrolled. Median age was 39 years (range, 20–58), and median
number of cryopreserved nucleated cells in the CB unit was 2.9 
107/kg (range, 2.0–4.7  107/kg). Their diagnoses were AML in 3
(2nd CR, 2; primary induction failure (PIF), 1), Ph1 ALL (1st
CR) in 2, advanced MDS in 2, and CML (2nd CP) in 1. All patients
achieved engraftment with full donor chimerism. Acute GVHD
occurred in 5 patients, and the grading was grade I in 2 and grade
II in 3 patients. Chronic GVHD occurred only in 2 patients. No
transplant-related mortality was observed, and overall survival was
100% with a median follow-up 14.7 months (range, 6.1–33.8
months). One patient with AML (PIF) relapsed 13 months after
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CBT.Conclusion:These results strongly suggested that unrelated
CBT could be safely used for adult patients with hematological
malignancies.
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FACTORS ASSOCIATED WITH CLINICAL OUTCOMES OF 483 ALLOGE-
NEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTS (PBSCT) IN BRA-
ZIL
Vigorito, A.C.1; Aranha, F.J.P.1; Oliveira, G.B.1; Eid, K.A.B.1; Lodi,
F.M.2; Azevedo, W.M.2; Colturato, V.3; De Souza, M.P.3; Barros,
J.C.4; Bittencourt, H.5; Silla, L.M.R.5; Brandalise, S.R.6; Pontes, E´.R.6;
Maiolino, A.7; Nucci, M.7; Ruiz, M.A.8; Zanichelli, M.A.9; De Souza,
C.A.1 1. State University of Campinas, Campinas, Sa˜o Paulo, Brazil; 2.
Federal University of Minas Gerais, Belo Horizonte, Minas Gerais,
Brazil; 3. Jau´ Center Hospital, Jau´, Sa˜o Paulo, Brazil; 4. Santa Casa de
Sa˜o Paulo Medical School, Sa˜o Paulo, Brazil; 5. Federal University of
Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; 6. Children
Hospital Dr. Boldrini, Campinas, Sa˜o Paulo, Brazil; 7. Federal Uni-
versity of Rio de Janeiro, Rio de Janeiro, Brazil; 8. Sa˜o Jose´ do Rio Preto
Medical School, Sa˜o Jose´ do Rio Preto, Sa˜o Paulo, Brazil; 9. Brigadeiro
Hospital, Sa˜o Paulo, Brazil.
Uncertainty still exists with the effects of allogeneic PBSCT on
the clinical outcomes of patients with hematological malignancies.
Our aim was analyzed retrospectively the clinical outcomes of 483
patients who underwent an allo PBSCT in 9 Brazilian centers from
May 1994 to February 2004. The analyses included patients with
hematological malignancies who underwent PBSCT from HLA
identical sibling donors. Median age was 34 (2–57), advanced
disease was present in 58%, conditioning without irradiation was
85%; GVHD prophylaxis with MTX/CsA was 91%; CD34 me-
dian was 4.7  106/kg (0.51–71.6); the median follow-up for
surviving patients was 797 days (8–3420); median day for neutro-
phils and platelets engraftment was 15 and 14, respectively; cumu-
lative incidence (CI) for 3 2 aGVHD was 38%; extensive cGVHD
63%; CI for transplant relate mortality (TRM) 59%; CI for relapse
37%; the estimates of OS and DFS at 9 ys are 33% and 42%,
respectively. In univariate analyses the following factors were as-
sociated with better outcome: for neutrophils and platelets engraft-
ment- CD34 cell dose 2.8 106/kg, GVHD prophylaxis other
than MTX/CsA, and sex match other than female donor for male
recipient; aGVHD- age 
43, and CD34 dose 4.7  106/kg;
cGVHD- age 
25 ys, sex match other than female donor for male
recipient, advanced disease and CD3 dose 
170  106/kg; OS-
early disease; DFS- early disease, and CD34 dose 4.7  106/kg;
relapse- age 25 ys, CD34 cell dose 2.8  106/kg, and early
disease; TRM- early disease. All the results remained signiﬁcant in
multivariate analyses, but for CD34 dose and platelet engraft-
ment; age and CD34 dose in aGVHD; age and CD3 in
cGVHD, and age in relapse. In our experience, sex match, CD34
dose, GVHD prophylaxis may inﬂuence the engraftment, and sex
match and disease phase the cGVHD. Furthermore, advanced
disease had a negative impact on OS and TRM. CD34 higher
dose and early disease were associated with better DFS and lower
relapse.
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FLUDARABINE-BASED CONDITIONING SECURES ENGRAFTMENT OF
SECONDARY HEMATOPOIETIC STEM CELL ALLOGRAFTS (HSCT) USED
TO TREAT GRAFT FAILURE
Chewning, J.H.1; Castro-Malaspina, H.R.2; Hsu, K.2; Jakubowski,
A.A.2; Kernan, N.A.1; Papadopoulos, E.B.2; Perales, M.-A.2; Prockop,
S.E.1; Small, T.N.1; Vandenbrink, M.R.M.2; Young, J.W.2; O’Reilly,
R.J.1; Boulad, F.1 1. Pediatrics-Bone Marrow Transplant Service, Me-
morial Sloan-Kettering Cancer Center, New York, NY; 2. Medicine-
Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer
Center, New York, NY.
Graft failure is associated with a high mortality rate. To date,
regimens invoked for secondary transplants have resulted in incon-
sistent engraftment with high transplant-related mortality. We
here report 15 patients, aged 4–59 years (median 24 years), who
received secondary HSCT (HSCT-2) following rejection of pri-
mary unmodiﬁed (N4) or T-cell depleted (N11) HSCT
(HSCT-1). HSCT-1 included myeloablative TBI- or alkylator-
based conditioning for acute leukemias (N5), MDS (N6), CML
(N3), and Fanconi anemia (N1). Cytoreduction regimens used
for HSCT-2 included: Fludarabine (Flu) alone (N2) or in com-
bination with Cyclophosphamide (CTX) (N8) or Thiotepa
(Thio) (N4), or Thio combined with CTX (N1). ATG (N11)
or Alemtuzumab (N3) was added pretransplant to prevent rejec-
tion. For HSCT-2, donors included: HLA-matched (N3) or
non-identical (N7) relatives and matched (N1) or non-identical
(N4) unrelated donors. The primary graft donor was used in
seven of ﬁfteen cases. The grafts administered were unmodiﬁed
PBSCT (N6) or BMT (N2) or T-cell depleted (TCD) PBSCT
(N7). Of 15 patients, 14 achieved engraftment with complete
chimerism. Mean time to engraftment (ANC 1000 for 3 days)
was 15.4 days. Seven patients died of infection (N5), graft failure
(N1), or encephalopathy (N1) within 100 days post-transplant,
and four patients succumbed to GVHD (N1), relapse (N1),
pneumonia (N1), or EBV lymphoma (N1) 6–15 months post-
transplant. Four patients are alive and disease-free with a median
follow-up of 51 months, including 3/8 conditioned with Flu/CTX.
In this limited series, younger patients (4/7
 20 years vs. 0/8 20
years), transplants from secondary donors (3/8 with secondary
donor vs. 1/7 with primary donor), and TCD HSCT-2 (3/7 TCD
vs. 1/8 unmodiﬁed) had a better outcome. In summary, secondary
HSCT following a Flu/ATG-based non-myeloablative regimen
have achieved consistent engraftment with hematopoietic recon-
stitution in patients with a primary graft failure, but are limited by
infections complicating delayed immune reconstitution.
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MYELOABLATIVE VS NON-MYELOABLATIVE CONDITIONING WITH AL-
LOGENEIC STEM CELL TRANSPLANTATION FOR HIGH RISK NON-
HODGKIN’S LYMPHOMA: SIMILAR OUTCOMES DESPITE DIFFERENCES
IN DISEASE RISK
Hewitt, M.; Porter, D.L.; Hummel, K.; McAlee, A.; Phillips, J.; Stadt-
mauer, E.; Schuster, S.; Luger, S.; Nasta, S.; Tsai, D.; Loren, A.; Perl,
A.; Emerson, S.; Goldstein, S.C. Blood and Marrow Stem Cell Trans-
plant Program at the University of Pennsylvania, Philadelphia, PA.
For patients (pts) with Non-Hodgkin’s Lymphoma (NHL), the
optimal timing and conditioning regimen intensity for transplant
has not been deﬁned. Nonmyeloablative stem cell transplants
(NMT) have been reserved for those patients at high risk for
treatment related morbidity and mortality (TRM) from conven-
tional High Dose allogeneic SCT (HDT) and have been increas-
ingly employed as salvage therapy for relapse after autotransplan-
tation. To assess the effectiveness of this approach, we performed
a retrospective analysis of 35 pts who have undergone either HDT
(n20) with a TBI-based regimen or NMT (n15) with a ﬂudara-
bine-based regimen followed by allogeneic SCT for high risk
NHL. Stem cell source varied by conditioning; 13/15 of HDT pts
received bone marrow (11 sib, 2 MUD), while all NMT pts
received peripheral blood (11 sib, 9 MUD). NMT pts constituted
a higher risk cohort based on extent of prior therapy (including
80% s/p autotransplant), chemoresistance, and age. Distribution of
histology for the entire group was skewed toward aggressive his-
tology, but equally distributed between HDT and NMT. For pts
surviving 90 days, median follow up for HDT pts is 50 months
(4–92 m), vs 12 months (4–45 m) for NMT pts. A comparison of
overall survival (53 vs 45%), event-free survival (53 vs 48%), and
progression-free survival (88 vs 64%) at 1 year demonstrated no
signiﬁcant differences between HDT and NMT cohorts despite
the higher risk nature of the NMT group. The 100-day TRM for
HDT vs NMT pts was similar (33 vs 30%, pns). The incidence
of grade II-IV acute GvHD was not signiﬁcantly different between
HDT (3/13 evaluable, 23%) and NMT (7/20, 35%). Among evalu-
able pts, chronic GvHD was lower in the HDT group vs NMT (13
vs 50%). Among causes of death, disease-related deaths were lower
in the HDT group (1/7, 14%) compared with NMT pts (5/11,
45%). This retrospective analysis demonstrates 1) NMT induces
durable remissions in a signiﬁcant number of poor risk pts; 2)
outcomes after NMT may be comparable to HDT; 3) relapse rates
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